2IU3
 
 | | Crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase | | 分子名称: | 1,5-DIHYDROIMIDAZO[4,5-C][1,2,6]THIADIAZIN-4(3H)-ONE 2,2-DIOXIDE, BIFUNCTIONAL PURINE BIOSYNTHESIS PROTEIN PURH, POTASSIUM ION | | 著者 | Xu, L, Chong, Y, Hwang, I, D'Onofrio, A, Amore, K, Beardsley, G.P, Li, C, Olson, A.J, Boger, D.L, Wilson, I.A. | | 登録日 | 2006-05-27 | | 公開日 | 2007-02-20 | | 最終更新日 | 2023-12-13 | | 実験手法 | X-RAY DIFFRACTION (2.9 Å) | | 主引用文献 | Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase.
J. Biol. Chem., 282, 2007
|
|
2IU0
 | | crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase | | 分子名称: | 1,5-DIHYDROIMIDAZO[4,5-C][1,2,6]THIADIAZIN-4(3H)-ONE 2,2-DIOXIDE, BIFUNCTIONAL PURINE BIOSYNTHESIS PROTEIN PURH, POTASSIUM ION | | 著者 | Xu, L, Chong, Y, Hwang, I, Onofrio, A.D, Amore, K, Beardsley, G.P, Li, C, Olson, A.J, Boger, D.L, Wilson, I.A. | | 登録日 | 2006-05-26 | | 公開日 | 2007-02-20 | | 最終更新日 | 2023-12-13 | | 実験手法 | X-RAY DIFFRACTION (2.53 Å) | | 主引用文献 | Structure-Based Design, Synthesis, Evaluation, and Crystal Structures of Transition State Analogue Inhibitors of Inosine Monophosphate Cyclohydrolase
J.Biol.Chem., 282, 2007
|
|
7U5G
 | | ACS122 Fab | | 分子名称: | ACS122 Fab Heavy chain, ACS122 Fab Light chain | | 著者 | Farokhi, E, Stanfield, R.L, Wilson, I.A. | | 登録日 | 2022-03-02 | | 公開日 | 2022-11-02 | | 最終更新日 | 2023-10-25 | | 実験手法 | X-RAY DIFFRACTION (1.84 Å) | | 主引用文献 | Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer.
Plos Pathog., 18, 2022
|
|
7JMX
 | | Crystal structure of a SARS-CoV-2 cross-neutralizing antibody COVA1-16 Fab | | 分子名称: | ACETATE ION, COVA1-16 heavy chain, COVA1-16 light chain, ... | | 著者 | Liu, H, Yuan, M, Zhu, X, Wu, N.C, Wilson, I.A. | | 登録日 | 2020-08-03 | | 公開日 | 2020-10-14 | | 最終更新日 | 2024-10-09 | | 実験手法 | X-RAY DIFFRACTION (2.53 Å) | | 主引用文献 | Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity.
Immunity, 53, 2020
|
|
7JMW
 | | Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutralizing antibody COVA1-16 Fab | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, COVA1-16 heavy chain, COVA1-16 light chain, ... | | 著者 | Liu, H, Yuan, M, Zhu, X, Wu, N.C, Wilson, I.A. | | 登録日 | 2020-08-03 | | 公開日 | 2020-10-14 | | 最終更新日 | 2024-10-23 | | 実験手法 | X-RAY DIFFRACTION (2.89 Å) | | 主引用文献 | Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity.
Immunity, 53, 2020
|
|
7U8L
 | |
7U8M
 | |
7U8J
 | |
7TI6
 | |
8V08
 | |
8V06
 | |
8V05
 | | Crystal structure of mouse PLD3 | | 分子名称: | 1,2-ETHANEDIOL, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 5'-3' exonuclease PLD3, ... | | 著者 | Yuan, M, Zhu, X, Wilson, I.A. | | 登録日 | 2023-11-17 | | 公開日 | 2024-03-13 | | 最終更新日 | 2024-10-30 | | 実験手法 | X-RAY DIFFRACTION (2.08 Å) | | 主引用文献 | Structural and mechanistic insights into disease-associated endolysosomal exonucleases PLD3 and PLD4.
Structure, 32, 2024
|
|
8V07
 | |
8V4I
 | | Structure of bovine anti-HIV Fab ElsE1 | | 分子名称: | ElsE1 Fab heavy chain, ElsE1 Fab light chain | | 著者 | Stanfield, R.L, Wilson, I.A. | | 登録日 | 2023-11-29 | | 公開日 | 2024-09-04 | | 最終更新日 | 2024-10-09 | | 実験手法 | X-RAY DIFFRACTION (1.81 Å) | | 主引用文献 | Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultra-long CDRH3 repertoire
To Be Published
|
|
2AFE
 | | Solution Structure of Asl1650, an Acyl Carrier Protein from Anabaena sp. PCC 7120 with a Variant Phosphopantetheinylation-Site Sequence | | 分子名称: | protein Asl1650 | | 著者 | Johnson, M.A, Peti, W, Herrmann, T, Wilson, I.A, Wuthrich, K, Joint Center for Structural Genomics (JCSG) | | 登録日 | 2005-07-25 | | 公開日 | 2005-08-16 | | 最終更新日 | 2024-05-22 | | 実験手法 | SOLUTION NMR | | 主引用文献 | Solution structure of Asl1650, an acyl carrier protein from Anabaena sp. PCC 7120 with a variant phosphopantetheinylation-site sequence
Protein Sci., 15, 2006
|
|
3P3T
 | |
2AFD
 | | Solution Structure of Asl1650, an Acyl Carrier Protein from Anabaena sp. PCC 7120 with a Variant Phosphopantetheinylation-Site Sequence | | 分子名称: | protein Asl1650 | | 著者 | Johnson, M.A, Peti, W, Herrmann, T, Wilson, I.A, Wuthrich, K, Joint Center for Structural Genomics (JCSG) | | 登録日 | 2005-07-25 | | 公開日 | 2005-08-16 | | 最終更新日 | 2024-05-22 | | 実験手法 | SOLUTION NMR | | 主引用文献 | Solution structure of Asl1650, an acyl carrier protein from Anabaena sp. PCC 7120 with a variant phosphopantetheinylation-site sequence
Protein Sci., 15, 2006
|
|
1DBK
 | |
2AJY
 | |
1DBM
 | |
2AK1
 | |
2AJX
 | |
3P3R
 | |
8VQN
 | | Crystal structure of the A/Puerto Rico/8/1934 (H1N1) influenza virus hemagglutinin in complex with small molecule 6R | | 分子名称: | (S~1~S,3R)-N-{3-chloro-4-[(2S)-2-phenylmorpholine-4-carbonyl]phenyl}-3-(dimethylamino)pyrrolidine-1-sulfonimidoyl fluoride, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Hemagglutinin HA1 chain, ... | | 著者 | Lin, T.H, Zhu, Y, Wilson, I.A. | | 登録日 | 2024-01-18 | | 公開日 | 2024-06-05 | | 最終更新日 | 2024-10-23 | | 実験手法 | X-RAY DIFFRACTION (2.21 Å) | | 主引用文献 | Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
8VQM
 | | Crystal structure of the A/Puerto Rico/8/1934 (H1N1) influenza virus hemagglutinin in complex with small molecule 6R prime | | 分子名称: | (S~1~S,3R)-N-{3,5-dichloro-4-[(2S)-2-phenylmorpholine-4-carbonyl]phenyl}-3-(dimethylamino)pyrrolidine-1-sulfonimidoyl fluoride, 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... | | 著者 | Lin, T.H, Zhu, Y, Wilson, I.A. | | 登録日 | 2024-01-18 | | 公開日 | 2024-06-05 | | 最終更新日 | 2024-11-06 | | 実験手法 | X-RAY DIFFRACTION (2.21 Å) | | 主引用文献 | Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry.
Proc.Natl.Acad.Sci.USA, 121, 2024
|
|
